pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 28·1 min read
save

Dementia finally shows a viable business model, AAIC2026 highlights economic shift

Jul 28, 2026·read at STAT ↗Positive

At the Alzheimer’s Association International Conference in London this year, the author observed that dementia now appears to have a clear business model, a shift from earlier meetings where commercial prospects were less certain.

Over the past nine years since the 2017 conference, the field has seen a surge in new treatments and diagnostic tools, turning scientific progress into market opportunities and attracting investment.

Groups such as the Davos Alzheimer’s Collaborative are actively building an innovation ecosystem, aiming to speed up breakthroughs, scale promising solutions, and equip health systems worldwide with the tools needed to address the growing dementia burden.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT+: Dementia finally has a business model”

read at STAT ↗
457 words · retrieved Jul 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGUniversity of Pennsylvania
topics
Alzheimer's Disease6Diagnostics CompanyNeurology

related stories

  • 7h agoTango plans 14% workforce cut, mainly of research staffBioSpace
  • Oct 14Opinion: We think a baby’s gut microbiome could be key to lifelong brain healthSTAT
  • Oct 6The top biopharma conferences in 2027BioPharma Dive
  • Sep 17Opinion: What happened to oppositional defiant disorder?STAT
  • Sep 16Opinion: STAT+: Dementia should be a campaign issue — not an insultSTAT